Allos Therapeutics, Inc. (Nasdaq: ALTH) announced the results from its Phase III study of Efaproxyn™ in patients with brain metastases. Results of the study, which were reported in the Journal of Clinical Oncology, suggest that the addition of Efaproxyn™ to whole brain radiation therapy may improve survival and response rates in patients with brain metastases, [...]

• 46View 2 Comments...http://clsdf.com/2006/01/allos-announces-survival-benefits-of-efaproxyn%e2%84%a2-in-phase-iii-study/Allos+Announces+Survival+Benefits+of+Efaproxyn%E2%84%A2+in+Phase+III+Study2006-01-09+21%3A14%3A00admin

Sirna Therapeutics, Inc. (Nasdaq: RNAI), is scheduled to present at the 24th Annual JPMorgan Healthcare Conference on Wednesday, January 11, 2006 at 4:00 p.m. PST. A live audio webcast of the presentation will be available at the Company’s web site at www.sirna.com. Sirna is a clinical-stage biotechnology company developing RNAi-based therapies for serious diseases and [...]

• 45View 1 Comment...http://clsdf.com/2006/01/sirna-to-webcast-jp-morgan-presentation/Sirna+to+Webcast+JP+Morgan+Presentation2006-01-09+21%3A04%3A00admin